Indivior PharmaceuticalsFRA:E7P +4.85%56 PE Ratio without NRI is 13.38 as of Jun. 25, 2026, which is 6% above its 10-year median of 12.59. GuruFocus rates FRA:E7P with a GF Score™ of 56/100 and a GF Value™ of €19.18 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 653 Drug Manufacturers companies, Indivior Pharmaceuticals ranks better than 69.22% on this metric.
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-06-25), Indivior Pharmaceuticals's share price is €34.60.
Indivior Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was €2.59. Therefore, Indivior Pharmaceuticals's PE Ratio without NRI for today is 13.38.
During the past 13 years, Indivior Pharmaceuticals's highest PE Ratio without NRI was 23.68. The lowest was 1.27. And the median was 12.59.
Indivior Pharmaceuticals (FRA:E7P) PE Ratio without NRI Explanation
The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.
If a company loses money, the PE Ratio becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.
Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.
Indivior Pharmaceuticals PE Ratio without NRI Related Terms
Indivior Pharmaceuticals PE Ratio without NRI Historical Data
* Premium members only.
The historical data trend for Indivior Pharmaceuticals's PE Ratio without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indivior Pharmaceuticals PE Ratio without NRI Chart
FRA:E7P vs AMRX, KNSA, LQDA: PE Ratio without NRI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Indivior Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indivior Pharmaceuticals PE Ratio without NRI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Indivior Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Indivior Pharmaceuticals's PE Ratio without NRI falls into.
Indivior Pharmaceuticals PE Ratio without NRI Calculation
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.
Indivior Pharmaceuticals's Share Price of today is €34.60.
Indivior Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.59.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.
For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Indivior Pharmaceuticals (FRA:E7P) has a PE Ratio without NRI of 13.38 as of Jun. 25, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Indivior Pharmaceuticals and its competitors. This is near median its historical median of 12.59. Over the past decade, Indivior Pharmaceuticals' PE Ratio without NRI has ranged from 1.27 to 23.68. According to the industry distribution chart, Indivior Pharmaceuticals ranks #201 out of 653 companies in the Drug Manufacturers industry, placing it in the top 30.8%.
Is Indivior Pharmaceuticals' PE Ratio without NRI too high?
Indivior Pharmaceuticals' current PE Ratio without NRI of 13.38 is near median its 10-year median of 12.59. Over the past 10 years, this metric has ranged from a low of 1.27 to a high of 23.68. The Drug Manufacturers industry median PE Ratio without NRI is 20.30. Indivior Pharmaceuticals' value of 13.38 is 34.1% below this industry median. Based on the distribution chart, Indivior Pharmaceuticals ranks #201 out of 653 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Indivior Pharmaceuticals has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Indivior Pharmaceuticals' PE Ratio without NRI compare to AMRX and KNSA?
According to the Drug Manufacturers industry distribution chart, Indivior Pharmaceuticals ranks #201 out of 653 companies for PE Ratio without NRI. This puts Indivior Pharmaceuticals in the upper half of its industry. The industry median PE Ratio without NRI is 20.30. Indivior Pharmaceuticals' value of 13.38 is 34.1% below this benchmark. Historically, Indivior Pharmaceuticals' own PE Ratio without NRI has ranged from 1.27 to 23.68 over the past decade. While the company's 10-year median is 12.59 vs. the industry median of 20.30, Indivior Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Drug Manufacturers company?
The median PE Ratio without NRI among Drug Manufacturers companies is 20.30, based on 653 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indivior Pharmaceuticals's current PE Ratio without NRI of 13.38 is 34.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Indivior Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PE Ratio without NRI is 20.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indivior Pharmaceuticals's current PE Ratio without NRI is 13.38, which is near median its own 10-year median of 12.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indivior Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Indivior Pharmaceuticals (FRA:E7P) is currently considered Significantly Overvalued. The stock's GF Value™ is €19.18, compared to a current price of €34.60 — trading 80.4% above its estimated fair value. The current PE Ratio without NRI is 13.38, which is near median its 10-year median of 12.59 and 34.1% below the Drug Manufacturers industry median of 20.30. Indivior Pharmaceuticals' overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Indivior Pharmaceuticals (FRA:E7P), the current PE Ratio without NRI is 13.38 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Indivior Pharmaceuticals (FRA:E7P) Overvalued in 2026?
Based on GuruFocus' analysis, Indivior Pharmaceuticals stock appears to be overvalued.
The current stock price of €34.60 is trading 80.4% above its estimated GF Value™ of €19.18.
GuruFocus considers Indivior Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:E7P:
PE Ratio without NRI: 13.38 (near median its 10-year median of 12.59)
GF Value™: €19.18 vs. price of €34.60 (80.4% above fair value)
Industry Position: 34.1% below the Drug Manufacturers median (#201 of 653)
No single metric tells the full story. See the FRA:E7P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
56GF Score
Get the complete analysis for FRA:E7P
PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:E7P has been successfully added to your 
